Shukra Pharmaceuticals Limited (BOM:524632)
India · Delayed Price · Currency is INR 51.96
-0.04 (-0.08%)
At close: Sep 4, 2026
Shukra Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 22,842 | 13,285 | 9,568 | 3,575 | 514 | 95 | |
Market Cap Growth | 87.58% | 38.86% | 167.65% | 595.01% | 443.89% | 35.73% |
Enterprise Value | 22,833 | 13,189 | 9,415 | 3,504 | 520 | 199 |
Last Close Price | 51.96 | 30.34 | 21.84 | 8.03 | 1.15 | 0.31 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 64.28 | 60.23 | 99.92 | 19.28 | 11.67 | 12.60 |
PS Ratio | 30.51 | 23.42 | 29.36 | 4.79 | 0.87 | 0.46 |
PB Ratio | 25.42 | 14.79 | 15.23 | 6.20 | 2.03 | 0.58 |
P/TBV Ratio | 25.42 | 14.79 | 15.23 | 6.20 | 2.03 | 0.58 |
P/FCF Ratio | - | - | 184.87 | - | - | 1.47 |
P/OCF Ratio | 581.04 | 337.94 | 120.83 | - | 16.23 | 1.18 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 30.50 | 23.25 | 28.89 | 4.70 | 0.88 | 0.97 |
EV/EBITDA Ratio | 45.31 | 39.58 | 60.91 | 16.18 | 8.01 | 6.78 |
EV/EBIT Ratio | 48.75 | 44.14 | 75.61 | 17.87 | 11.17 | 15.63 |
EV/FCF Ratio | - | - | 181.91 | - | - | 3.09 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.06 | 0.06 | 0.07 | 0.06 | 0.20 | 0.21 |
Debt / EBITDA Ratio | 0.10 | 0.15 | 0.27 | 0.15 | 0.78 | 1.15 |
Debt / FCF Ratio | - | - | 0.81 | - | - | 0.52 |
Net Debt / Equity Ratio | -0.01 | -0.01 | -0.13 | -0.12 | 0.04 | 0.19 |
Net Debt / EBITDA Ratio | -0.02 | -0.03 | -0.51 | -0.31 | 0.17 | 1.05 |
Net Debt / FCF Ratio | - | 0.08 | -1.53 | 0.98 | -0.84 | 0.48 |
Asset Turnover | - | 0.56 | 0.40 | 0.98 | 1.08 | 0.58 |
Inventory Turnover | - | 1.33 | 1.35 | 16.28 | 12.78 | 3.73 |
Quick Ratio | - | 1.25 | 2.33 | 2.89 | 1.00 | 0.62 |
Current Ratio | - | 3.63 | 3.79 | 3.97 | 1.25 | 1.28 |
Return on Equity (ROE) | - | 28.89% | 15.90% | 44.70% | 21.16% | 4.70% |
Return on Assets (ROA) | - | 18.29% | 9.46% | 16.04% | 5.29% | 2.25% |
Return on Invested Capital (ROIC) | 39.29% | 31.85% | 16.91% | 47.35% | 20.16% | 4.24% |
Return on Capital Employed (ROCE) | - | 31.70% | 17.90% | 30.80% | 14.40% | 5.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.49% | 1.66% | 1.00% | 5.19% | 8.57% | 7.94% |
FCF Yield | -0.52% | -0.89% | 0.54% | -1.95% | -2.57% | 68.08% |
Dividend Yield | 0.02% | 0.03% | 0.05% | 1.24% | 1.09% | 4.06% |
Payout Ratio | - | 1.98% | 45.73% | 0.38% | 1.65% | - |
Buyback Yield / Dilution | 7.31% | -0.75% | - | -551.03% | -7.38% | - |
Total Shareholder Return | 7.33% | -0.72% | 0.05% | -549.78% | -6.29% | 4.06% |